SHANGHAI, May 3, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2012 on May 17, 2012. Management will host a conference call to discuss the results at 8:00AM New York Time on May 17, 2012 ( 8:00PM Beijing Time on May 17, 2012).
Mr. Michael Xin Hui, founder and Chief Executive Officer; Mr. William Dai, Chief Financial Officer; and Ms. Lan Xie, Vice President of Finance and Investor Relations, will discuss the results and take questions following the prepared remarks.
Dial-in details for the live conference call are as follows:International: +1-718-354-1231 United States: +1-866-519-4004 United Kingdom: 080-8234-6646 Hong Kong: +852-2475-0994 Passcode: SHP A live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com. A telephone replay of the call will be available for seven days from May 17, 2012, 11:00AM U.S. Eastern Time to May 24, 2012, 11:59PM U.S. Eastern Time. The dial-in details for the replay are as follows: International: +61-2-8235-5000Passcode: 78479978 ABOUT SHANGPHARMA CORPORATION ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. For further information, please contact:
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts